Key Highlights
- First-half Revenue rose 5% to £863.8m and adjusted operating profit climbed about 8% to £171.1m
- The adjusted Operating Margin widened to 19.8% from 19.3% a year earlier
- Electric Thermal Solutions led divisional growth with sales up around 11%, supported by semiconductor demand
- The Interim Dividend was raised 3% to 50.4p, continuing a multi-decade record of increases
- Full-year guidance was reaffirmed, with growth and margin gains weighted towards the second half
Spirax Group (LSE:SPX), the Cheltenham-based maker of steam systems, electric heating and precision pumps, delivered a steadier first half than the market has grown used to. Revenue for the six months to 30 June 2026 rose to £863.8m, adjusted operating profit advanced to £171.1m, and the board lifted the interim dividend for another year. After a bruising stretch of currency drag, restructuring and a share price that has more than halved from its pandemic-era peak, management framed the numbers as evidence that its strategy is working. The reported figures support cautious optimism rather than a decisive breakout — the recovery is real, but early, and heavily weighted to the second half.
Company and news background
Spirax is one of the London market's more unusual industrials. It sells almost entirely through its own engineers rather than distributors, which gives it close contact with customers across food, pharmaceuticals, energy and semiconductors. The group runs three divisions: Steam Thermal Solutions, its heritage business; Electric Thermal Solutions, built around the Chromalox and Vulcanic electric-heating brands; and Watson-Marlow Fluid Technology Solutions, a high-margin peristaltic-pump operation with heavy exposure to biopharma.
The company rebranded from Spirax-Sarco Engineering in 2024 and set out medium-term targets that October under chief executive Nimesh Patel. The half-year results, released on 11 August 2026, are the latest test of whether those ambitions are on track after two difficult years dominated by weak global industrial production, destocking in life sciences and a strong pound.
The numbers that matter
Group revenue of £863.8m was up 5% on the £822.2m reported a year earlier, with organic growth in the mid-single digits — comfortably ahead of global industrial production, which has been running barely above flat. Adjusted operating profit rose about 8% to £171.1m, and the adjusted operating margin widened to 19.8% from 19.3%, restoring some of the profitability the group prizes.
Statutory operating profit climbed sharply, by around 44%, but that headline flatters the underlying picture: the prior-year comparative was depressed by restructuring charges tied to the group's cost programme, which is targeting roughly £35m of annual savings. Strip that out and the operational improvement is solid rather than spectacular. The interim dividend was raised 3% to 50.4p, continuing an unbroken multi-decade record of increases.
Cash generation was the softer note. Adjusted cash conversion fell to 54% from 61%, reflecting seasonal patterns and Investment in inventory, while return on Capital employed improved by around 180 basis points. Net Debt sat at roughly 1.6 times EBITDA, leaving the Balance Sheet comfortably within the group's comfort zone. With reported growth of 5% sitting alongside mid-single-digit organic growth, currency looks to have been broadly neutral this half — a relief after a 2025 in which the strong pound knocked several points off both sales and profit.
What is driving the story
The divisional split tells the real tale. Electric Thermal Solutions led the way with sales up around 11%, powered by continued strength in the semiconductor sector, where Chromalox supplies heating for chip fabrication. Watson-Marlow rose about 7% as biopharma order books recovered from the destocking that hollowed out Demand across the industry in 2023 and 2024. Steam Thermal Solutions, the largest and most economically sensitive division, managed only about 1% — but management stressed that underlying demand grew at roughly twice the pace of industrial production, with recovery in China and Korea and resilient maintenance and repair spending.
Patel said the group had "again delivered resilient mid-single-digit organic growth in revenue and profit, well ahead of IP," and insisted Spirax remained "on track to deliver the medium-term targets we set out for the Group in October 2024; and above these targets in the longer term." Crucially, full-year guidance was reaffirmed: mid-single-digit organic revenue growth well ahead of industrial production, and a further increase in the adjusted operating margin, with both weighted towards the second half.
What it means for investors
The bull case rests on quality and momentum. Spirax combines high margins, a direct sales model that is hard to replicate, structural exposure to decarbonisation and life sciences, and a dividend record that few UK companies can match. If industrial production genuinely troughs and biopharma capital spending keeps recovering, the second-half weighting in guidance implies accelerating growth into 2027. Semiconductor demand adds a genuine growth vector that the old steam-only Spirax lacked.
The bear case is about pace and price. Steam's 1% growth shows the core Franchise is still barely moving; cash conversion has slipped; and the recovery leans on a second half that has not yet arrived. Above all there is valuation. Even after a severe de-rating from its 2021 highs above £160, the shares still change hands on a price-earnings multiple in the mid-thirties and command a Market Value of roughly £5bn. Spirax has historically earned a premium rating for its consistency, but that premium leaves little room for disappointment if the promised second-half acceleration falls short.
Competitively, the group remains well positioned against peers such as Halma and Rotork, and its balance sheet — geared at about 1.6 times EBITDA — comfortably funds both the dividend and continued investment. The question for shareholders is less whether the Business is good and more whether the price already assumes the turnaround is complete.
What comes next
The immediate watch-points are second-half delivery and the trajectory of margins, since management has explicitly back-loaded its guidance. Investors will want to see Steam Thermal Solutions build on its early-cycle signals, Watson-Marlow sustain the biopharma recovery, and cash conversion normalise towards the group's usual high-80s range by the full year. Any further wobble in Chinese industrial demand, a renewed swing in sterling, or fresh Tariff friction could quickly unpick the story.
On the evidence of these results, Spirax is recovering rather than accelerating. Profit rose, margins improved and the dividend grew again, all of which vindicate the strategy after a punishing period. But calling this the start of a new growth cycle would be premature: the numbers describe a well-run business finding its feet as its end markets thaw, with the decisive proof deferred to the closing months of the year. For a share still priced for excellence, execution in the second half will matter more than the reassurance offered today.



_11_18_2026_13_53_59_733490.jpg)


Please wait processing your request...